SOLUBLE ZCYTOR21, ANTI-ZCYTOR21 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION

The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. Zcyto...

Full description

Saved in:
Bibliographic Details
Main Authors LEWIS, KATHERINE E, LEVIN, STEVEN D, JASPERS, STEPHEN R, OKADA, SHANNON L, GAO, ZEREN, KUIJPER, JOSEPH L, KUESTNER, ROLF E, TAFT, DAVID W, MCKERNAN, PATRICIA A, APPLEBY, MARK W
Format Patent
LanguageEnglish
French
Published 27.04.2006
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners. La présente invention concerne des antagonistes ZcytoR21 tels que les récepteurs et les anticorps anti-ZcytoR21 solubles, utiles dans le blocage, l'inhibition, la réduction, l'antagonisation ou la neutralisation de l'activité d'IL-17C. IL-17C est une cytokine impliquée dans le processus inflammatoire ou les maladies de l'humain. ZcytoR21 est un récepteur pour IL-17C. La présente invention concerne ZcytoR21, un anticorps anti-ZcytoR21 et des partenaires de liaison ainsi que des procédés pour antagoniser IL-17 C au moyen de ces récepteurs solubles, ces anticorps et ces partenaires de liaison solubles.
Bibliography:Application Number: CA20052584078